MDNA-223

N/A

Report date: 2025/01/26 17:22:19

Base Information

Drug NameMDNA-223

Drug Alias Nameanti-PD1 antibody linked to an IL-2 super-agonist (Medicenna Therapeutics)PD-1 checkpoint inhibitor linked to an IL-2 super-agonist (Medicenna Therapeutics)anti-PD1-IL-2 BiSKITMDNA-223

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionInterleukin-2 receptor agonistsProgrammed cell death protein 1 blockers

TargetsInterleukin-2 receptorProgrammed cell death protein 1

Therapy Area/IndicationsSkin NeoplasmsColonic NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMedicenna Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesMedicenna Therapeutics Corp

Inactive CompaniesN/A

Active IndicationsSkin NeoplasmsColonic NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A